Trials / Completed
CompletedNCT05000086
A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is aim to evaluate the efficacy and safety of technetium \[99Tc\] methylene diphosphonate (99Tc-MDP, trade name: Yunke) in the treatment of psoriatic arthritis.
Detailed description
This is a single-arm, open label, 24 weeks study. Patients with psoriatic arthritis get 99Tc-MDP 22mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 99Tc methylene diphosphonate | 22mg qd，Once a day for 7 consecutive days |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2021-08-11
- Last updated
- 2021-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05000086. Inclusion in this directory is not an endorsement.